Form 4: Ionis EVP Swayze Reports Equity Transactions

Ionis Pharmaceuticals' EVP of Research, Eric Swayze, reported significant equity transactions including RSU vesting, new RSU and PRSU grants, and tax-related stock sales.

Summary

• Eric Swayze, EVP Research at Ionis Pharmaceuticals, acquired 21,366 shares of common stock directly and 111 shares indirectly through his son on January 15, 2026, due to the vesting of Restricted Stock Unit (RSU) awards.
• On January 16, 2026, Swayze disposed of 9,884 shares directly at a weighted average price of $75.34 and 49 shares indirectly through his son at $75.97. These sales were automatic to cover tax withholding obligations related to the RSU vesting.
• Swayze was granted 25,800 Performance Restricted Stock Units (PRSUs) on January 15, 2026, which may vest based on the Issuer's relative total shareholder return over a three-year period, with a maximum potential payout of 200% of the target number.
• Additionally, Swayze received a grant of 9,675 Restricted Stock Units (RSUs) directly and 225 RSUs indirectly through his son on January 15, 2026, which vest in four equal annual installments.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation activities, including significant new equity grants (RSUs and PRSUs) which align executive incentives with long-term company performance. While there are tax-related sales, these are standard and expected upon vesting. The new PRSU grant, in particular, is a positive sign of continued commitment and performance-based incentives.

Positives

• Grant of 25,800 Performance Restricted Stock Units (PRSUs) to Eric Swayze, aligning his incentives with shareholder return.
• Grant of 9,675 Restricted Stock Units (RSUs) directly to Eric Swayze and 225 RSUs indirectly to his son, representing future equity compensation.
• Vesting of 21,366 common shares directly and 111 common shares indirectly from previous RSU awards.

Negatives

• Sale of 9,884 common shares directly and 49 common shares indirectly to cover tax withholding obligations, reducing direct beneficial ownership.

Risks

• The actual number of Performance Restricted Stock Units (PRSUs) that will vest may range from zero to the maximum reported amount (25,800 PRSUs), depending on the Issuer's relative total shareholder return compared to a peer group over a three-year performance period.

Future Outlook

The Performance Restricted Stock Units (PRSUs) granted to Eric Swayze are tied to the Issuer's relative total shareholder return over a three-year performance period ending January 15, 2029, indicating a future focus on long-term shareholder value. Other Restricted Stock Units (RSUs) will vest in four equal annual installments, providing ongoing equity compensation.

Industry Context

This Form 4 filing details routine executive equity compensation and tax-related transactions, which are common practices in the biotechnology and pharmaceutical industry to align executive incentives with company performance and shareholder interests. The use of Performance Restricted Stock Units (PRSUs) is a standard mechanism for linking executive pay to specific performance metrics, such as relative total shareholder return, which is a common practice among peer companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Restricted Stock Units (PRSUs) for executive compensation is a standard practice across the biotechnology and pharmaceutical industry, similar to companies like Amgen, Gilead Sciences, and Biogen.
• Tying PRSU vesting to relative total shareholder return against a peer group is a common governance practice designed to incentivize outperformance compared to competitors.
• Automatic sales to cover tax withholding obligations upon RSU vesting are a routine and expected part of equity compensation plans for executives in publicly traded companies.

Related Party Transactions

• Grant of 225 Restricted Stock Units (RSUs) to Eric Swayze's son.
• Indirect beneficial ownership and tax-related sale of 49 common shares by Eric Swayze's son.

Stakeholder Impact

• Shareholders: The grant of Performance Restricted Stock Units (PRSUs) aligns executive incentives with shareholder returns, potentially benefiting long-term shareholder value if performance targets are met. Routine RSU vesting and grants are part of the company's compensation strategy.
• Employees: The equity compensation structure for executives may reflect broader compensation philosophies within the company.

Next Steps

• Continued vesting of Restricted Stock Units (RSUs) in four equal annual installments.
• Evaluation of Performance Restricted Stock Units (PRSUs) vesting based on the Issuer's relative total shareholder return over a three-year performance period ending January 15, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation and tax-related transactions, which are expected and pre-planned. It does not contain new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The grants of new equity, particularly performance-based units, are a positive for long-term alignment but do not fundamentally alter the investment thesis for Ionis Pharmaceuticals at this time.

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Insider Trading, Equity Incentive Plan, Restricted Stock Units, Performance Restricted Stock Units, Executive Compensation, Eric Swayze, Stock Vesting, Tax Withholding